ClearPoint Neuro, Inc. (CLPT)
| Market Cap | 349.08M -9.2% |
| Revenue (ttm) | 40.61M +26.0% |
| Net Income | -29.07M |
| EPS | -1.01 |
| Shares Out | 29.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 727,218 |
| Open | 12.36 |
| Previous Close | 12.77 |
| Day's Range | 11.61 - 12.56 |
| 52-Week Range | 8.27 - 30.10 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+89.0%) |
| Earnings Date | May 13, 2026 |
About CLPT
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint softwa... [Read more]
Financial Performance
In 2025, ClearPoint Neuro's revenue was $36.97 million, an increase of 17.78% compared to the previous year's $31.39 million. Losses were -$25.54 million, 35.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CLPT stock is "Strong Buy." The 12-month stock price target is $22.0, which is an increase of 89.00% from the latest price.
News
ClearPoint Neuro receives CE Marking for Velocity Alpha MR
ClearPoint Neuro (CLPT) announced that the Velocity Alpha MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States.
ClearPoint Neuro reports Q1 EPS (32c) vs. (22c) last year
Reports Q1 revenue $12.1M vs. $8.5M last year. Neurosurgery navigation, therapy and access revenue increased 80% to $5.9M, driven by additional revenues from sales of the IRRAflow product and the…
ClearPoint Neuro sees FY26 revenue $52M-$56M, consensus $53.03M
The company expects cost synergies resulting from the acquisition of IRRAS to contribute to a reduction in cash burn in the second half of 2026 and believes the asset integration…
ClearPoint Neuro Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue of $12.1M (43% growth) driven by organic and IRRAflow contributions, with gross margin up to 64%. 2026 revenue is guided at $52–$56M, all segments expected to grow double digits, and integration synergies are improving margins and global reach.
ClearPoint Neuro Reports First Quarter 2026 Results
Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a globa...
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain ...
ClearPoint Neuro resumed with a Buy at Stifel
Stifel analyst Tom Stephan resumed coverage of ClearPoint Neuro (CLPT) with a Buy rating and $16 price target ClearPoint is well-positioned in the large neurological disorder market with its “robust”…
ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...
ClearPoint Neuro announces first clinical use of Velocity Alpha MR drill
ClearPoint Neuro (CLPT) announced the successful completion of the first clinical procedure utilizing the 510(k)-cleared Velocity Alpha MR High Speed Surgical Drill System. “The design of the drill bi...
ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brai...
ClearPoint Neuro announces Canadian approval for Neuro Navigation System
ClearPoint Neuro (CLPT) announced receipt of a Medical Device License from Health Canada for its Neuro Navigation System, further expanding our Drug Delivery ecosystem and global footprint. Covering b...
ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ove...
ClearPoint Neuro price target raised to $20 from $18 at B. Riley
B. Riley raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $18 and keeps a Buy rating on the shares. ClearPoint Neuro reported mixed Q4 results with…
ClearPoint Neuro Earnings Call Transcript: Q4 2025
2025 saw record revenue growth, a successful IRRAS acquisition, and strong momentum into 2026, with all core segments expected to grow double digits. Guidance for 2026 is $52M–$56M, reflecting FDA and integration factors, and long-term targets remain ambitious.
ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
Record Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company...
ClearPoint Neuro options imply 11.2% move in share price post-earnings
Pre-earnings options volume in ClearPoint Neuro (CLPT) is normal with calls leading puts 5:1. Implied volatility suggests the market is anticipating a move near 11.2%, or $1.26, after results are…
ClearPoint Neuro options imply 6.2% move in share price post-earnings
Pre-earnings options volume in ClearPoint Neuro (CLPT) is 1.5x normal with calls leading puts 54:1. Implied volatility suggests the market is anticipating a move near 6.2%, or 0c, after results…
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026
SOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the b...
ClearPoint Neuro price target lowered to $18 from $28 at B. Riley
B. Riley lowered the firm’s price target on ClearPoint Neuro (CLPT) to $18 from $28 and keeps a Buy rating on the shares. ClearPoint Neuro shares fell about 30% after…
ClearPoint Neuro options imply 15.3% move in share price post-earnings
Pre-earnings options volume in ClearPoint Neuro (CLPT) is normal with calls leading puts 7:1. Implied volatility suggests the market is anticipating a move near 15.3%, or $1.96, after results are…
ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati...
ClearPoint Neuro files to sell 1.31M shares of common stock for holders
The company is not selling any shares of common stock pursuant to this prospectus, and will not receive any proceeds from the sale of any shares offered by this prospectus…
ClearPoint Neuro sees Q4 revenue $10.4M, up 20% y/y
ClearPoint Neuro (CLPT) announced preliminary unaudited revenue growth for its fourth quarter of 2025. These preliminary unaudited financial results are management’s estimates, are subject to revision...
ClearPoint Neuro sees FY26 revenue $54M-$60M
The Company continues to expect total revenues in 2026 between $54 and $60 million driven by the combination of organic growth and the completion of integration activities for the IRRAflow…
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (th...